Lv11
10 积分 2025-05-29 加入
AHEAD-MERIT: A Phase II/III Trial of First Line (1L) BNT113 Plus Pembrolizumab in Unresectable Recurrent or Metastatic HPV16+ HNSCC
5小时前
已完结
An iPSC-derived CD19/BCMA CAR-NK therapy in a patient with systemic sclerosis
17天前
已完结
Anti–CD19 CAR T Cells in Refractory Immune Thrombocytopenia of SLE
1个月前
已完结
Intravesical T3011, an IL-12/anti-PD-1 armed oncolytic HSV-1, in BCG-naïve high-risk NMIBC: A phase IIa trial
1个月前
已完结
Progress of phase II study of MVR-T3011, an IL-12/anti-PD-1 armed oncolytic HSV-1, in high-risk BCG-unresponsive CIS and papillary NMIBC
1个月前
已完结
Human papillomavirus vaccination coverage and willingness among women in mainland China: A meta-analysis based on the COM-B model
2个月前
已关闭
Development and Assessment of a Computerized Index of Clinical Disease Activity in Systemic Lupus Erythematosus
3个月前
已完结
The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessment
3个月前
已完结
系统性红斑狼疮疾病活动评分评估系统性红斑狼疮疾病活动的临床价值研究
3个月前
已完结
Autologous CD19 CAR T-cell therapy for pediatric and adult systemic lupus erythematosus: a phase 1/2 trial
3个月前
已完结
皖公网安备34019202002308
